BioXcel Therapeutics Inc. has completed enrollment in its open-label clinical study aimed at evaluating the correlation between patient-and informant-reported mCGI-S measurement and the Positive and Negative Syndrome Scale-Excitatory Component (PEC) scale. Conducted by trained raters, this study involves approximately 30 patients. The company anticipates releasing the results in the fourth quarter of 2025. These findings, along with results from the already announced SERENITY At-Home Pivotal Phase 3 Safety Trial, will be part of the clinical package for the supplemental New Drug Application (sNDA) submission, expected in the first quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioXcel Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-089773), on September 15, 2025, and is solely responsible for the information contained therein.